Streetbeat News

Analyst Ratings

PCRX

HC Wainwright & Co. analyst Oren Livnat maintains a 'Buy' rating on Pacira BioSciences (NASDAQ:PCRX) but lowers the price target from $63 to $57.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:33 am

COMP

Needham analyst Bernie McTernan has maintained a 'Buy' rating on Compass (NYSE:COMP) but lowered the price target from $5.5 to $4.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:29 am

BTM

HC Wainwright & Co. analyst Mike Colonnese has initiated coverage on Bitcoin Depot (NASDAQ:BTM) with a Buy rating and a price target of $6.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:27 am

TKR

Keybanc analyst Steve Barger has maintained an Overweight rating on Timken (NYSE:TKR) but lowered the price target from $102 to $91.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:27 am

SIX

Keybanc analyst Noah Zatzkin has maintained an Overweight rating on Six Flags Entertainment (NYSE:SIX) but lowered the price target from $31 to $28.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:25 am

QSR

Keybanc analyst Eric Gonzalez maintains an Overweight rating on Restaurant Brands Intl (NYSE:QSR) but lowers the price target from $85 to $82.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:23 am

DKNG

Needham analyst Bernie McTernan maintains a Buy rating on DraftKings (NASDAQ:DKNG) and raises the price target from $44 to $50.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:22 am

WEST

Telsey Advisory Group analyst Sarang Vora has reiterated an 'Outperform' rating on Westrock Coffee (NASDAQ:WEST) and maintained a $14 price target.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:21 am

ES

Eversource Energy reported Q3 earnings of $0.97 per share, missing the analyst consensus estimate of $0.99 by 2.02%. The company's quarterly sales were $2.79 billion, missing the estimate of $3.29 billion by 15.28%. This represents a decrease in earnings and sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:06 am

FENC

Fennec Pharmaceuticals reported Q3 earnings per share (EPS) of $(0.07), beating the analyst consensus estimate of $(0.11) by 36.36%. This is a 77.42% increase over losses from the same period last year. The company also reported quarterly sales of $6.51 million, beating the analyst consensus estimate of $5.42 million by 20.20%.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:05 am